Clinical Trial Update: Repeated Endobiliary Radiofrequency Ablation Plus Durvalumab, Gemcitabine, and Cisplatin for Unresectable Extrahepatic Cholangiocarcinoma [NA]

View source ↗

Summary

Clinical trial update for a study evaluating repeated endobiliary radiofrequency ablation in combination with durvalumab, gemcitabine, and cisplatin in patients…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extrahepatic Cholangiocarcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Durvalumab (Imfinzi) (durvalumab)
• Gemcitabine (Gemzar) (gemcitabine)

Snippet

Sponsor: Aichi Medical University | Conditions: Extrahepatic Cholangiocarcinoma | NA | Status: RECRUITING